This article was originally published in The Gray Sheet
In vitro blood test for the human equivalent of mad cow disease, Creutzfeldt-Jacob disease (CJD), will be developed by the Ortho-Clinical Diagnostics unit of Johnson & Johnson under an exclusive, worldwide license agreement with Caprion Pharmaceuticals. The test will be based on prion technologies related to the monoclonal antibodies for CJD. Roche and Prionics also inked an agreement earlier this year for development of a CJD blood test (1"The Gray Sheet" Jan. 29, 2001, In Brief)...
You may also be interested in...
The American Red Cross will retain a 74% equity stake in a joint venture with ProMetic Life Sciences to develop systems for detection and removal of transmissible spongiform encephalopathy (TSE) pathogens from blood and blood components
Firms will collaborate in development of a blood test for the detection of Creutzfeldt-Jacob disease in humans under an agreement announced Jan. 24. CJD is related to bovine spongiform encephalopathy (BSE), or "mad cow disease." The deal also calls for Roche to distribute the Prionics-Check rapid test for the detection of BSE in dead cattle effective Feb. 1
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.